# Evaluation of Immunogenicity and Safety of Combined Immunization of sIPV, DTaP and MMR

> **NCT04638985** · PHASE4 · UNKNOWN · sponsor: **China National Biotec Group Company Limited** · enrollment: 600 (estimated)

## Conditions studied

- Vaccine

## Interventions

- **BIOLOGICAL:** sIPV+DTaP+MMR
- **BIOLOGICAL:** sIPV
- **BIOLOGICAL:** DTaP
- **BIOLOGICAL:** MMR

## Key facts

- **NCT ID:** NCT04638985
- **Lead sponsor:** China National Biotec Group Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-11-13
- **Primary completion:** 2021-09
- **Final completion:** 2021-12
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2020-12-10

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04638985

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04638985, "Evaluation of Immunogenicity and Safety of Combined Immunization of sIPV, DTaP and MMR". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04638985. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*